{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chimérisme : Questions médicales les plus fréquentes",
"headline": "Chimérisme : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chimérisme : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-28",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chimérisme"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Aberrations des chromosomes",
"url": "https://questionsmedicales.fr/mesh/D002869",
"about": {
"@type": "MedicalCondition",
"name": "Aberrations des chromosomes",
"code": {
"@type": "MedicalCode",
"code": "D002869",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.365.590.175"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Chimérisme",
"alternateName": "Chimerism",
"code": {
"@type": "MedicalCode",
"code": "D046528",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hui Li",
"url": "https://questionsmedicales.fr/author/Hui%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States; Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States. Electronic address: hl9r@virginia.edu."
}
},
{
"@type": "Person",
"name": "Sandeep Singh",
"url": "https://questionsmedicales.fr/author/Sandeep%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States."
}
},
{
"@type": "Person",
"name": "Hao Zhang",
"url": "https://questionsmedicales.fr/author/Hao%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China. haozhang@jnu.edu.cn."
}
},
{
"@type": "Person",
"name": "Xinrui Shi",
"url": "https://questionsmedicales.fr/author/Xinrui%20Shi",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States."
}
},
{
"@type": "Person",
"name": "Yusheng Lin",
"url": "https://questionsmedicales.fr/author/Yusheng%20Lin",
"affiliation": {
"@type": "Organization",
"name": "Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Shikonin derivatives cause apoptosis and cell cycle arrest in human chondrosarcoma cells via death receptors and MAPK regulation.",
"datePublished": "2022-07-12",
"url": "https://questionsmedicales.fr/article/35820864",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-022-09857-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Liproxstatin‑1 induces cell cycle arrest, apoptosis, and caspase‑3/GSDME‑dependent secondary pyroptosis in K562 cells.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36004469",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3892/ijo.2022.5409"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of acetone fraction of Ottelia alismoides on the G2/M cell cycle arrest and apoptosis in the human carcinoma cell lines.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36162544",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jep.2022.115729"
}
},
{
"@type": "ScholarlyArticle",
"name": "Aspergillus Carneus metabolite Averufanin induced cell cycle arrest and apoptotic cell death on cancer cell lines via inducing DNA damage.",
"datePublished": "2023-04-20",
"url": "https://questionsmedicales.fr/article/37081051",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-30775-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, and Angiogenesis Inhibition in Triple-Negative Breast Cancer Cells.",
"datePublished": "2023-09-09",
"url": "https://questionsmedicales.fr/article/37764312",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules28186536"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Variation génétique",
"item": "https://questionsmedicales.fr/mesh/D014644"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mutation",
"item": "https://questionsmedicales.fr/mesh/D009154"
},
{
"@type": "ListItem",
"position": 5,
"name": "Aberrations des chromosomes",
"item": "https://questionsmedicales.fr/mesh/D002869"
},
{
"@type": "ListItem",
"position": 6,
"name": "Chimérisme",
"item": "https://questionsmedicales.fr/mesh/D046528"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chimérisme - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chimérisme",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chimérisme",
"description": "Comment diagnostiquer le chimérisme ?\nQuels tests sont utilisés pour le chimérisme ?\nLe chimérisme peut-il être détecté par échographie ?\nQuels signes cliniques peuvent indiquer un chimérisme ?\nLe chimérisme est-il héréditaire ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Cell+Cycle+Checkpoints&page=8#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chimérisme",
"description": "Quels sont les symptômes du chimérisme ?\nLe chimérisme cause-t-il des douleurs ?\nPeut-on avoir des symptômes sans chimérisme ?\nLe chimérisme affecte-t-il la croissance ?\nY a-t-il des symptômes spécifiques au chimérisme ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Cell+Cycle+Checkpoints&page=8#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chimérisme",
"description": "Peut-on prévenir le chimérisme ?\nY a-t-il des facteurs de risque pour le chimérisme ?\nLes tests prénataux peuvent-ils détecter le chimérisme ?\nLe chimérisme est-il lié à des pratiques médicales ?\nLes femmes enceintes doivent-elles se méfier du chimérisme ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Cell+Cycle+Checkpoints&page=8#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chimérisme",
"description": "Comment traiter le chimérisme ?\nLe chimérisme nécessite-t-il une intervention chirurgicale ?\nLes médicaments peuvent-ils aider au chimérisme ?\nY a-t-il des traitements naturels pour le chimérisme ?\nLe suivi médical est-il nécessaire pour le chimérisme ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Cell+Cycle+Checkpoints&page=8#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chimérisme",
"description": "Quelles complications peuvent survenir avec le chimérisme ?\nLe chimérisme peut-il causer des cancers ?\nComment gérer les complications du chimérisme ?\nLe chimérisme affecte-t-il le système immunitaire ?\nY a-t-il des risques de rejet avec le chimérisme ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Cell+Cycle+Checkpoints&page=8#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chimérisme",
"description": "Quels sont les facteurs de risque du chimérisme ?\nLe chimérisme est-il plus fréquent chez certaines populations ?\nLes greffes augmentent-elles le risque de chimérisme ?\nLes antécédents médicaux influencent-ils le chimérisme ?\nLe chimérisme est-il lié à des facteurs environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Cell+Cycle+Checkpoints&page=8#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer le chimérisme ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par analyse génétique, notamment par PCR ou séquençage."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le chimérisme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'analyse de l'ADN, les tests de compatibilité tissulaire et les marqueurs génétiques."
}
},
{
"@type": "Question",
"name": "Le chimérisme peut-il être détecté par échographie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'échographie ne peut pas détecter le chimérisme, seul un test génétique est fiable."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent indiquer un chimérisme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques peuvent inclure des anomalies immunitaires ou des différences phénotypiques."
}
},
{
"@type": "Question",
"name": "Le chimérisme est-il héréditaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le chimérisme n'est généralement pas héréditaire, il résulte d'événements embryonnaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du chimérisme ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, mais peuvent inclure des anomalies cutanées ou des troubles immunitaires."
}
},
{
"@type": "Question",
"name": "Le chimérisme cause-t-il des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le chimérisme en soi ne cause pas de douleurs, mais des complications peuvent en entraîner."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans chimérisme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux symptômes peuvent être causés par d'autres conditions médicales."
}
},
{
"@type": "Question",
"name": "Le chimérisme affecte-t-il la croissance ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut affecter la croissance si des anomalies génétiques ou hormonales sont présentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au chimérisme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des différences de pigmentation ou des anomalies immunitaires peuvent être spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le chimérisme ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le chimérisme ne peut pas être prévenu car il résulte d'événements embryonnaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque pour le chimérisme ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des grossesses multiples ou des transfusions sanguines."
}
},
{
"@type": "Question",
"name": "Les tests prénataux peuvent-ils détecter le chimérisme ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests prénataux standard ne détectent pas le chimérisme, des tests génétiques spécifiques sont nécessaires."
}
},
{
"@type": "Question",
"name": "Le chimérisme est-il lié à des pratiques médicales ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines pratiques comme les greffes peuvent augmenter le risque de chimérisme."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles se méfier du chimérisme ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de mesures préventives spécifiques pour les femmes enceintes concernant le chimérisme."
}
},
{
"@type": "Question",
"name": "Comment traiter le chimérisme ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend des symptômes et peut inclure des thérapies immunosuppressives."
}
},
{
"@type": "Question",
"name": "Le chimérisme nécessite-t-il une intervention chirurgicale ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, sauf si des complications graves nécessitent une intervention spécifique."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider au chimérisme ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments immunosuppresseurs peuvent être prescrits pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour le chimérisme ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitements naturels prouvés pour le chimérisme, consultez un médecin."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il nécessaire pour le chimérisme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller les complications potentielles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le chimérisme ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles immunitaires, des rejets de greffe ou des cancers."
}
},
{
"@type": "Question",
"name": "Le chimérisme peut-il causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines formes de chimérisme peuvent augmenter le risque de cancers spécifiques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications du chimérisme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des traitements adaptés aux symptômes."
}
},
{
"@type": "Question",
"name": "Le chimérisme affecte-t-il le système immunitaire ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le chimérisme peut entraîner des dysfonctionnements du système immunitaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de rejet avec le chimérisme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le rejet peut survenir si des cellules étrangères sont reconnues par le système immunitaire."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du chimérisme ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les grossesses multiples et les transfusions sanguines sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Le chimérisme est-il plus fréquent chez certaines populations ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de données précises, mais les grossesses multiples peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les greffes augmentent-elles le risque de chimérisme ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les greffes d'organes peuvent introduire des cellules étrangères, entraînant un chimérisme."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le chimérisme ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de transfusions ou de greffes peuvent augmenter le risque de chimérisme."
}
},
{
"@type": "Question",
"name": "Le chimérisme est-il lié à des facteurs environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de preuves solides liant le chimérisme à des facteurs environnementaux."
}
}
]
}
]
}
Although chondrosarcoma is the second most common primary malignant bone tumor, treatment options are limited due to its extensive resistance to a chemo- and radiation therapy. Since shikonin has show...
The dose-relationships of shikonin and its derivatives acetylshikonin and cyclopropylshikonin on two human chondrosarcoma cell lines were measured using the CellTiter-Glo®. The changes in the cell cyc...
Chondrosarcoma cells showed a dose-dependent inhibition of cell viability after treatment with shikonin and its derivatives, with the strongest effect for shikonin and IC...
These data demonstrated the significant anti-tumorigenic effect of shikonin derivatives in chondrosarcoma and encourage further research....
Leukemia is a fatal hematopoietic disorder with a poor prognosis. Drug resistance is inevitable after the long‑term use of chemotherapeutic agents. Liproxstatin‑1, commonly known as a ferroptosis inhi...
The North-eastern parts of India have immense therapeutic floras, Ottelia alismoides is an aquatic plant that has been in use for a long time in traditional medicine for treating diseases like cancer,...
The purpose of this study was to evaluate the apoptotic potential of acetone extract of O. alismoides (L.) Pers. (OA-AC) and to identify the compounds responsible for this effect, HRLC-MS-QTOF analysi...
A549 and A431 cells were treated with acetone extract of O. alismoides (OA-AC) at 24 h and 48 h exposure and cell cycle phase distribution was evaluated and also apoptosis induction activity was evalu...
The cell cycle phase distribution analysis in A549 and A431 cells at 24hrs exposure with 10 μg/mL and 25 μg/mL of OA-AC showed a potent arrest or blockage at the G2/M phase of the cell cycle with redu...
AO-EtBr staining of these cancer cells reveals that the death induced by OA-AC was apoptotic in nature with depolarization of mitochondrial membrane due to loss or damage of the mitochondrial membrane...
Cancer is one of the leading causes of death worldwide, accounting for nearly 10 million deaths in 2020. Current treatment methods include hormone therapy, γ-radiation, immunotherapy, and chemotherapy...
The absence of progesterone receptors, estrogen receptors, and human epidermal growth factor receptor-2 restricts the therapy choices for treating triple-negative breast cancer (TNBC). Moreover, conve...
Hepatocellular carcinoma (HCC) is the major lethal primary liver malignant worldwide. Although, melatonin has various antitumor bioactivities; there is a requirement for more investigations to elucida...
Heterologous expression of recombinant ion channel subunits in cell lines is often limited by the presence of a low number of channels at the cell surface level. Here, we introduce a combination of tw...
Chemotherapy with targeted drugs is the first line therapy option for acute and chronic myeloid leukemia. However, hematopoietic stem cell transplantation may be used in high-risk patients or patients...
Hypoxia plays a vital role in tumor microenvironment by allowing development and maintenance of cancer cells thereby led to major hindrance for effective anticancer therapy and main reason for failure...
Bromuconazole, a fungicide belonging to the triazole family, is a plant protection product used to control, repel or destroy fungi that may develop on crops. We investigated the pro-apoptotic effect o...
The human colon HCT116 cell line was treated with Bromuconazole (IC50/4, IC50/2, and IC50) for 24 h. Cells were collected and analysed for biomarkers of apoptotic cell death and oxidative stress as we...
Our study showed that bromuconazole caused a concentration-dependent increase in cell mortality with an IC50 of 180 µM. Bromuconazole induced cell cycle arrest in the G0/G1 phase and DNA synthesis inh...
Bromuconazole toxicity was through the oxidative stress process, which causes DNA damage and mitochondrial dysfunction, leading to cell cycle arrest and apoptotic death of HCT116 cells....